-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
Immucillins -X- _ B-Intervention
ImmA -X- _ I-Intervention
( -X- _ I-Intervention
IA -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ I-Intervention
ImmH -X- _ I-Intervention
( -X- _ I-Intervention
IH -X- _ I-Intervention
) -X- _ I-Intervention
and -X- _ I-Intervention
SerMe-ImmH -X- _ I-Intervention
( -X- _ I-Intervention
SMIH -X- _ I-Intervention
) -X- _ I-Intervention
are -X- _ O
synthetic -X- _ O
deazapurine -X- _ O
nucleoside -X- _ O
analogues -X- _ O
that -X- _ O
inhibit -X- _ O
Leishmania -X- _ B-Patient
( -X- _ I-Patient
L. -X- _ I-Patient
) -X- _ I-Patient
infantum -X- _ I-Patient
chagasi -X- _ I-Patient
and -X- _ I-Patient
Leishmania -X- _ I-Patient
( -X- _ I-Patient
L. -X- _ I-Patient
) -X- _ I-Patient
amazonensis -X- _ I-Patient
multiplication -X- _ O
in -X- _ O
vitro -X- _ O
without -X- _ O
macrophage -X- _ O
toxicity. -X- _ O
Immucillins -X- _ B-Intervention
are -X- _ O
compared -X- _ O
to -X- _ O
the -X- _ O
Glucantime -X- _ B-Comparison
standard -X- _ I-Comparison
drug -X- _ I-Comparison
in -X- _ O
the -X- _ O
chemotherapy -X- _ O
of -X- _ O
Leishmania -X- _ B-Patient
( -X- _ I-Patient
L. -X- _ I-Patient
) -X- _ I-Patient
infantum -X- _ I-Patient
chagasi -X- _ I-Patient
infection -X- _ I-Patient
in -X- _ I-Patient
mice -X- _ I-Patient
and -X- _ I-Patient
hamsters. -X- _ I-Patient
These -X- _ O
agents -X- _ O
are -X- _ O
tested -X- _ O
for -X- _ O
toxicity -X- _ O
and -X- _ O
immune -X- _ O
system -X- _ O
response. -X- _ O
METHODOLOGY -X- _ O
/ -X- _ O
PRINCIPAL -X- _ O
FINDINGS -X- _ O
: -X- _ O
BALB -X- _ B-Patient
/ -X- _ I-Patient
c -X- _ I-Patient
mice -X- _ I-Patient
were -X- _ O
infected -X- _ O
with -X- _ O
10 -X- _ B-Intervention
( -X- _ I-Intervention
7 -X- _ I-Intervention
) -X- _ I-Intervention
amastigotes -X- _ I-Intervention
, -X- _ I-Intervention
treated -X- _ I-Intervention
with -X- _ I-Intervention
IA -X- _ I-Intervention
, -X- _ I-Intervention
IH -X- _ I-Intervention
, -X- _ I-Intervention
SMIH -X- _ I-Intervention
or -X- _ O
Glucantime -X- _ B-Comparison
( -X- _ I-Comparison
2.5mg -X- _ I-Comparison
/ -X- _ I-Comparison
kg -X- _ I-Comparison
/ -X- _ I-Comparison
day -X- _ I-Comparison
) -X- _ I-Comparison
and -X- _ O
monitored -X- _ O
for -X- _ O
clinical -X- _ O
variables -X- _ O
, -X- _ O
parasite -X- _ O
load -X- _ O
, -X- _ O
antibody -X- _ O
levels -X- _ O
and -X- _ O
splenocyte -X- _ O
IFN-γ -X- _ O
, -X- _ O
TNF-α -X- _ O
, -X- _ O
and -X- _ O
IL-10 -X- _ O
expression. -X- _ O
Cytokines -X- _ O
and -X- _ O
CD4+ -X- _ O
, -X- _ O
CD8+ -X- _ O
and -X- _ O
CD19+ -X- _ O
lymphocyte -X- _ O
frequencies -X- _ O
were -X- _ O
assessed -X- _ O
in -X- _ O
uninfected -X- _ O
controls -X- _ O
and -X- _ O
in -X- _ O
response -X- _ O
to -X- _ O
immucillins. -X- _ O
Urea -X- _ O
, -X- _ O
creatinine -X- _ O
, -X- _ O
GOT -X- _ O
and -X- _ O
GPT -X- _ O
levels -X- _ O
were -X- _ O
monitored -X- _ O
in -X- _ O
sera. -X- _ O
Anti- -X- _ B-Outcome
Leishmania-specific -X- _ I-Outcome
IgG1 -X- _ I-Outcome
antibodies -X- _ I-Outcome
( -X- _ I-Outcome
anti-NH36 -X- _ I-Outcome
) -X- _ I-Outcome
increased -X- _ I-Outcome
in -X- _ I-Outcome
untreated -X- _ I-Outcome
animals. -X- _ I-Outcome
IgG2a -X- _ I-Outcome
response -X- _ I-Outcome
, -X- _ I-Outcome
high -X- _ I-Outcome
levels -X- _ I-Outcome
of -X- _ I-Outcome
IFN-γ -X- _ I-Outcome
, -X- _ I-Outcome
TNF-α -X- _ I-Outcome
and -X- _ I-Outcome
lower -X- _ I-Outcome
levels -X- _ I-Outcome
of -X- _ I-Outcome
IL-10 -X- _ I-Outcome
were -X- _ I-Outcome
detected -X- _ I-Outcome
in -X- _ I-Outcome
mice -X- _ I-Outcome
treated -X- _ I-Outcome
with -X- _ I-Outcome
the -X- _ I-Outcome
immucillins -X- _ I-Outcome
and -X- _ I-Outcome
Glucantime. -X- _ I-Outcome
Immucillins -X- _ I-Outcome
permitted -X- _ I-Outcome
normal -X- _ I-Outcome
weight -X- _ I-Outcome
gain -X- _ I-Outcome
, -X- _ I-Outcome
prevented -X- _ I-Outcome
hepato- -X- _ I-Outcome
splenomegaly -X- _ I-Outcome
and -X- _ I-Outcome
cleared -X- _ I-Outcome
the -X- _ I-Outcome
parasite -X- _ I-Outcome
infection -X- _ I-Outcome
( -X- _ I-Outcome
85–89 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
without -X- _ I-Outcome
renal -X- _ I-Outcome
and -X- _ I-Outcome
hepatic -X- _ I-Outcome
toxicity. -X- _ I-Outcome
Immucillins -X- _ I-Outcome
promoted -X- _ I-Outcome
35 -X- _ I-Outcome
% -X- _ I-Outcome
lower -X- _ I-Outcome
secretion -X- _ I-Outcome
of -X- _ I-Outcome
IFN-γ -X- _ I-Outcome
in -X- _ I-Outcome
uninfected -X- _ I-Outcome
controls -X- _ I-Outcome
than -X- _ I-Outcome
in -X- _ I-Outcome
infected -X- _ I-Outcome
mice. -X- _ I-Outcome
IA -X- _ I-Outcome
and -X- _ I-Outcome
IH -X- _ I-Outcome
increased -X- _ I-Outcome
the -X- _ I-Outcome
CD4+ -X- _ I-Outcome
T -X- _ I-Outcome
and -X- _ I-Outcome
CD19+ -X- _ I-Outcome
B -X- _ I-Outcome
cell -X- _ I-Outcome
frequencies. -X- _ I-Outcome
SMIH -X- _ I-Outcome
increased -X- _ I-Outcome
only -X- _ I-Outcome
the -X- _ I-Outcome
proportion -X- _ I-Outcome
of -X- _ I-Outcome
CD-19 -X- _ I-Outcome
B -X- _ I-Outcome
cells. -X- _ I-Outcome
IA -X- _ I-Outcome
and -X- _ I-Outcome
IH -X- _ I-Outcome
also -X- _ I-Outcome
cured -X- _ I-Outcome
infected -X- _ I-Outcome
hamsters -X- _ I-Outcome
with -X- _ I-Outcome
lower -X- _ I-Outcome
toxicity -X- _ I-Outcome
than -X- _ I-Outcome
Glucantime. -X- _ I-Outcome
CONCLUSIONS -X- _ O
/ -X- _ O
SIGNIFICANCE -X- _ O
: -X- _ O
Immucillins -X- _ B-Outcome
IA -X- _ I-Outcome
, -X- _ I-Outcome
IH -X- _ I-Outcome
and -X- _ I-Outcome
SMIH -X- _ I-Outcome
were -X- _ I-Outcome
effective -X- _ I-Outcome
in -X- _ I-Outcome
treating -X- _ I-Outcome
leishmaniasis -X- _ I-Outcome
in -X- _ I-Outcome
mice. -X- _ I-Outcome
In -X- _ I-Outcome
hamsters -X- _ I-Outcome
, -X- _ I-Outcome
IA -X- _ I-Outcome
and -X- _ I-Outcome
IH -X- _ I-Outcome
were -X- _ I-Outcome
also -X- _ I-Outcome
effective. -X- _ I-Outcome
The -X- _ I-Outcome
highest -X- _ I-Outcome
therapeutic -X- _ I-Outcome
efficacy -X- _ I-Outcome
was -X- _ I-Outcome
obtained -X- _ I-Outcome
with -X- _ I-Outcome
IA -X- _ I-Outcome
, -X- _ O
possibly -X- _ O
due -X- _ O
to -X- _ O
its -X- _ O
induction -X- _ O
of -X- _ O
a -X- _ O
TH1 -X- _ O
immune -X- _ O
response. -X- _ O
Low -X- _ O
immucillin -X- _ O
doses -X- _ O
were -X- _ O
required -X- _ O
and -X- _ O
showed -X- _ O
no -X- _ O
toxicity. -X- _ O
Our -X- _ O
results -X- _ O
disclose -X- _ O
the -X- _ O
potential -X- _ O
use -X- _ O
of -X- _ O
IA -X- _ O
and -X- _ O
IH -X- _ O
in -X- _ O
the -X- _ O
therapy -X- _ O
of -X- _ O
visceral -X- _ O
leishmaniasis -X- _ O
. -X- _ O

